Aptiv Solutions and Cancer genetics have partnered to provide biopharmaceutical developers with support for cancer trials.
The new accord, details of which were not provided, will combine the firms’ respective capabilities in trial design, regulatory affairs and pharmacovigilance with CGI operational support services.
Biomarkers will be a key focus of the partnership according to Aptiv CMO Gene Resnick, who explained that they play a key role in improving development decisions, particularly in the field of oncology.
“We recognize the critical role of biomarkers in the development of new agents in oncology and other therapeutic areas,” said Resnick, going on to say that “Adding this capacity to our existing expertise in oncology trial management will bring a value-add for sponsors and ultimately for patients.”
CGI CEO Panna Sharma offered a similar opinion, commeting that: “As a leader in personalized medicine, CGI is confident that this collaboration will assist our clients in the development of new therapeutics and diagnostics by reducing the time frame and costs for regulatory approval through patient stratification.”